Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2546469 | 0.82 | STS (0.42) | ALDH1A1TSHRLMNAGAACYP2D6 | |
| SCHEMBL4279441 | 0.81 | LMNA (0.52) | ALDH1A1LMNAKMT2AMEN1KDM4E | |
| SCHEMBL14856170 | 0.79 | TSHR (0.50) | ADORA3ALDH1A1TSHRCYP3A4LMNA | |
| SCHEMBL1491521 | 0.78 | EPHX1 (0.55) | ALDH1A1EPHX2KDM4EHTTPOLB | |
| SCHEMBL27761137 | 0.78 | STS (0.57) | LMNAKMT2APKMGAACYP2D6 | |
| SCHEMBL631325 | 0.77 | ALDH1A1 (0.61) | ADORA3ALDH1A1TSHRCYP3A4LMNA | |
| SCHEMBL28262946 | 0.77 | ALDH1A1 (0.52) | ADORA3ALDH1A1TSHRCYP3A4LMNA | |
| SCHEMBL1287302 | 0.75 | CYP2D6 (0.45) | ADORA3ALDH1A1TSHRCYP3A4LMNA | |
| Butane SCHEMBL2149677 | 0.75 | ALDH1A1 (0.55) | ADORA3ALDH1A1TSHRCYP3A4LMNA | |
| Cyclamic Acid SCHEMBL4613995 | 0.74 | ALDH1A1 (0.67) | ADORA3ALDH1A1TSHRCYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2580193-B1 | BENZAMIDE DERIVATIVES AND THEIR USE AS HSP90 INHIBTORS | CHROMA THERAPEUTICS LTD (GB) | 2016-07-20 | — | — | EP | disclosed |
| US-20160193200-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS HSP90 INHIBTORS | CHROMA THERAPEUTICS LTD. (GB) | 2016-07-07 | — | — | US | disclosed |
| US-9321718-B2 | Benzamide derivatives and their use as HSP90 inhibtors | CHROMA THERAPEUTICS LTD. (GB) | 2016-04-26 | — | — | US | disclosed |
| US-20130143926-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS HSP90 INHIBTORS | CHROMA THERAPEUTICS LTD. (GB) | 2013-06-06 | — | — | US | disclosed |
| EP-2580193-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS HSP90 INHIBTORS | Chroma Therapeutics Ltd. (GB) | 2013-04-17 | — | — | EP | disclosed |
| WO-2011154708-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS HSP90 INHIBTORS | CHROMA THERAPEUTICS LTD (GB) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160193200-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS HSP90 INHIBTORS | HSP90AB1, HSP90AA1, HSP90AB2P | ADORA3 3133/4885ALDH1A1 1146/4885TSHR 1457/4885 |
| US-20130143926-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS HSP90 INHIBTORS | HSP90AB1, HSP90AA1, HSP90AB2P | ADORA3 3133/4885ALDH1A1 1146/4885TSHR 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.